An observational study in Glioma, sponsored by Centre Hospitalier Universitaire de Nice. Completed at 1 site in France. Open to participants aged 19 Years to 77 Years. Per ClinicalTrials.gov, last updated 2021-02-16.
Sponsored by Centre Hospitalier Universitaire de Nice · Observational
WHO classification of low grade gliomas now relies on tumoral molecular patterns, especially on IDH mutation and 1p/19q co deletion status. Textural analysis on medical imaging is studied in several fields, and could provide help in patients with brain tumor due to possible complications of brain biopsy. The purpose of this study is to determine if specific textural signature on MR imaging could be found for low grade gliomas. The investigators included patients with LGG diagnosed at CHU of Nice abd whose first MRI was available on the PACS of the CHU. Textural data are extraxted by tumoral contouring and specific logiciel (LifeX) and histopathologic data are assessed for each patient. Then the investigators analyze it to dtermine if textural indices can predict molecar status.
1,397 studies on the registry are indexed under Glioma; 351 are open to participants now.
This study's enrollment of 80 is close to the median of 88 across 238 observational studies indexed under Glioma.
Browse Glioma studies →Centre Hospitalier Universitaire de Nice is the lead sponsor of 709 studies on the registry; 176 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Lower grade gliomas diagnosed at CHU of Nice with pre operative MRI and molecular data available
LGG diagnosed at CHU of Nice abd whose first MRI was available on the PACS of the CHU
Exclusion Criteria:
-
review of MRI images to find clues that can predict molecular status
Time frame: 9 years
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Nice